We describe characteristics of 17 patients with a Zika virus (ZIKV) infection seen in a Travel Center in Paris during the 4 months following the WHO alert on ZIKV. Sixteen were imported cases, including 13 from the Caribbean. One was a women living in Paris infected through sexual transmission. One case was a pregnant woman. All cases were symptomatic with fever, fatigue and cutaneous rash in 15/17, 13/17, and 16/17, respectively. Leucopenia was observed in 6/17, thrombopenia in 2/17. Diagnosis was confirmed by ZIKV RT-PCR (plasma: 12/17; urine 15/17) or detection of ZIKV IgM (2/17). Two patients were hospitalized but all evolved well.
Introduction
The current Zika virus (ZIKV) outbreak is spreading since virus was first detected in Brazil in March 2015. By mid-June 2016, cases of autochthonous infections were observed in 60 countries. Most of these cases were in South America and the Caribbean. 1, 2 By mid-June, 838 imported cases were reported in 20 countries of the European Union. Among these, 535 occurred in Continental France between January 1 and June 23 2016. 3, 4 Most cases of ZIKV are asymptomatic or mildly symptomatic; however, a substantial number of cases with neurologic disorders were observed. Thirteen countries reported an increase in Guillain Barre's syndrome incidence, while concomitant neurological disorders were found in three patients with ZIKV in Guadeloupe. 2, [5] [6] [7] Moreover, infants born to infected mothers are at risk of having malformations, including a 0.95% higher risk of having microcephaly. 8 The objective of this study was to evaluate the extent of imported ZIKV cases in a Parisian travel unit within 4 months following the WHO declaration of Public Health Emergency of International Concern for cluster of microcephaly cases and other neurological disorders attributed to ZIKV (ZIKV PHEIC). 9 
Methods
The study was conducted at Bichat-Claude Bernard hospital (BCB), a university hospital located in the North of Paris. Data were collected prospectively at the Travel Diseases Centre of the Infectious and Tropical Diseases department.
Cases were defined as patients with confirmed ZIKV infection [as proven by a positive test for plasma or urine ZIKV RT-PCR, or by detection of immunoglobulin M antibodies (IgM) of Depending on the date of symptom onset, plasma samples of patients were systematically screened for Dengue and Chikungunya using the following methods: detection of NS1 antigen in plasma sample (Bio-rad, France) for quick diagnosis of dengue, detection of Dengue and Chikungunya RNA by realtime RT-PCR (Fast-Track Diagnostics, Luxembourg) or detection of specific antibodies (Capture Elisa, Pandio Australia for Dengue and Elisa Euroimmun France for Chikungunya). Detection of RNA was performed when onset occurred up to 5 days prior to the test, while detection of antibodies was performed when onset occurred more than 5 days prior to the test.
Results
Seventeen patients were diagnosed with ZIKV: five in February, three in March, four in April and five in May. The presence of ZIKV was confirmed in all 17 cases by a positive ZIKV RT-PCR result (plasma: 12/17; urine 15/17) or detection of ZIKV IgM (2/17). Among these patients, ten were women, including one pregnant woman (gestational term at her first visit ¼13 weeks), and seven men. The mean age was 42 years (range 24-62 years). Although most cases were returning from The Caribbean (13/17), four cases were returning from other regions in the epidemic area. One case (Case no. 4) had not travelled to a ZIKV endemic area: she was infected through sexual intercourse with a convalescent man returning from Brazil (Case no. 5). 10 Patient's clinical and biological characteristics are shown in Table 1 . All cases were symptomatic. The most common symptoms, fever, fatigue and cutaneous rash, were observed in 15/17, 13/17 and 16/17 cases, respectively. Nonpurulent conjunctivitis (n ¼ 1), retro orbital pain (n ¼ 1) and peripheral oedema (n ¼ 1) were less frequently observed. In 7/17 patients, blood tests showed leucopoenia, due to lymphopenia (n ¼ 6; median lymphocyte count 1.51 G/l [1.01;2.17]) and/or neutropenia (n ¼ 5, median neutrophils count: 2.43 [1.45;3.50]). Platelet counts tended to be low (median platelets count 235 G/l [166;288]) and were below 150 G/l in two cases. Two cases (nos. 16 and 17) required hospitalization. Case no. 16 had severe hepatic cytolysis and diagnostic uncertainty; she eventually evolved well. On the other hand, Case no. 17 was hospitalized due to regressive hemiparesis, that was unrelated to ZIKV (normal MRI and normal lumbar puncture).
All cases evolved well during the 5-month follow-up period. The foetal outcome of the pregnant woman, monitored by ultrasound scan, reported a mild ventriculomegaly at 6 months of pregnancy. Since this version, the mother delivered and the newborn is in good condition.
Discussion
During the 4 months following ZIKV PHEIC, 17 ZIKV cases were diagnosed in the travel centre of a Parisian hospital. This number reflects the impact of ZIKV outbreak in a non-endemic country. France is one of the most affected countries in Europe but many others have reported imported cases. USA reported 755 travel-related cases by 15 June 2016, including 189 pregnant women. 4, 11 In addition, ten countries reported non-vector-borne ZIKV infections, acquired mainly through sexual intercourse. 3, 10 One should be reminded that imported ZIKV cases seen in clinics reflect only a very small portion of the epidemic, as up to 80% of ZIKV infections are asymptomatic. 5 Many countries have thus implemented guidelines to manage patients, particularly pregnant women with proven or suspected ZIKV. French guidelines recommend ZIKV serology 30-40 days after returning from endemic zones for pregnant women and monthly foetal echography for those diagnosed with ZKV infection.
11-13 CDC guidelines recommend foetal ultrasound followup every 3-4 weeks for infected mothers and also systematic ultrasound screening for microcephaly and microcalcifications in mothers with negative biological testing.
11
Additional guidelines were also published for prevention of sexual transmission, recommending the use of condom or abstinence for at least 8 weeks following return from area with active ZIKV, and 6 months for men who are confirmed to have ZIKV or display clinical illness consistent with ZIKV disease. [11] [12] [13] The number of ZIKV cases reported in continental France is strongly related to the ZIKV epidemic in French territories (West Indies and Guyana), and to the high frequency of trips between these areas.
14 Nevertheless, ZIKV may still be imported by travellers back from other areas than Caribbean and Central/ South America, as shown by a recent report from China where four of nine imported cases were acquired in Pacific islands (Samoa and Fidji). 15 In conclusion, ZIKV is a medical concern in travel units in non-endemic countries, especially in USA and France, that may grow further. Indeed, the next Olympic Games in Brazil will increase the human flow towards and from South America. This highlights the attention that healthcare providers should give to imported ZIKV diagnosis.
